Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694994 | 0.82 | ALDH1A1 (0.43) | TSHRLMNATYRALOX5APGAA | |
| SCHEMBL18649029 | 0.81 | MAPK1 (0.42) | LMNAALOX5APCNR2MEN1NPC1 | |
| SCHEMBL24817396 | 0.81 | TSHR (0.41) | TSHRLMNATYREPHX2NR1H4 | |
| SCHEMBL24304080 | 0.81 | PDE2A (0.32) | — | |
| SCHEMBL25819138 | 0.81 | PDE2A (0.35) | ALOX5AP | |
| SCHEMBL26879793 | 0.79 | ESR1 (0.44) | TSHREPHX2NR1H4TP53ESRRG | |
| SCHEMBL18800291 | 0.78 | ALOX5AP (0.33) | ALOX5AP | |
| SCHEMBL23621640 | 0.78 | AR (0.34) | CACNA1H | |
| SCHEMBL19323005 | 0.76 | CNR2 (0.41) | LMNAEPHX2NR1H4TP53CNR2 | |
| SCHEMBL14062415 | 0.76 | KIF11 (0.47) | TSHRAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-11-28 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20220033369-A1 | HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-02-03 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | TSHR 4785/4885LMNA 334/4885TYR 4742/4885 |
| US-20220033369-A1 | HYDROXAMIC ACID DERIVATIVE, METHOD FOR PRODUCING SAME AND USE THEREOF | HACL2, NAAA, LCT | TSHR 3939/4885LMNA 1731/4885TYR 3440/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | TSHR 4218/4885LMNA 373/4885TYR 3339/4885 |
| US-11827612-B2 | Hydroxamic acid derivative, method for producing same and use thereof | HACL2, NAAA, LCT | TSHR 3939/4885LMNA 1731/4885TYR 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.